Giuseppina Capra

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3069386/publications.pdf

Version: 2024-02-01

33	731	471061 17	525886 27
papers	citations	h-index	g-index

34	34	34	1073
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Proliferative verrucous vs conventional leukoplakia: no significantly increased risk of HPV infection. Oral Oncology, 2004, 40, 835-840.	0.8	73
2	Detection of oncogenic human papillomavirus genotypes on spermatozoa from male partners of infertile couples. Fertility and Sterility, 2013, 100, 1236-1240.	0.5	62
3	Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations. International Journal of Cancer, 2013, 132, 2528-2536.	2.3	56
4	Detection of Human Papillomavirus DNA in Cervical Samples: Analysis of the New PGMY-PCR Compared To the Hybrid Capture II and MY-PCR Assays and a Two-Step Nested PCR Assay. Journal of Clinical Microbiology, 2004, 42, 3861-3864.	1.8	41
5	Presence of Rickettsia conorii subsp. israelensis , the Causative Agent of Israeli Spotted Fever, in Sicily, Italy, Ascertained in a Retrospective Study. Journal of Clinical Microbiology, 2005, 43, 6027-6031.	1.8	38
6	Brushing of Oral Mucosa for Diagnosis of HPV Infection in Patients with Potentially Malignant and Malignant Oral Lesions. Molecular Diagnosis and Therapy, 2006, 10, 49-55.	1.6	37
7	HPV genotype prevalence in cytologically abnormal cervical samples from women living in south Italy. Virus Research, 2008, 133, 195-200.	1.1	37
8	Penile, Urethral, and Seminal Sampling for Diagnosis of Human Papillomavirus Infection in Men. Journal of Clinical Microbiology, 2007, 45, 248-251.	1.8	32
9	Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily. Human Vaccines and Immunotherapeutics, 2017, 13, 1839-1843.	1.4	31
10	HPV groupâ€•and typeâ€šspecific concordance in HPV infected sexual couples. Journal of Medical Virology, 2007, 79, 1882-1888.	2.5	27
11	Identification and Characterization of a Constitutive HSP75 in Sea Urchin Embryos. Biochemical and Biophysical Research Communications, 1997, 234, 24-29.	1.0	26
12	Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients. Vaccines, 2021, 9, 714.	2.1	25
13	Analysis of persistence of human papillomavirus infection in men evaluated by sampling multiple genital sites. European Review for Medical and Pharmacological Sciences, 2015, 19, 4153-63.	0.5	23
14	Oral HPV Infection: Current Strategies for Prevention and Therapy. Current Pharmaceutical Design, 2012, 18, 5452-5469.	0.9	22
15	HPV infection in semen: results from a new molecular approach. Epidemiology and Infection, 2019, 147, e177.	1.0	21
16	HPV infection in relation to OSCC histological grading and TNM stage. Evaluation by traditional statistics and fuzzy logic model. Oral Oncology, 2006, 42, 638-645.	0.8	19
17	Helicobacter pylori and Epsteinâ€“Barr Virus Infection in Gastric Diseases: Correlation with IL-10 and IL1RN Polymorphism. Journal of Oncology, 2019, 2019, 1-8.	0.6	19
18	Unusual MRI findings in an immunocompetent patient with EBV encephalitis: a case report. BMC Medical Imaging, 2011, 11, 6.	1.4	17

#	Article	IF	Citations
19	Impact of a new carrageenan-based vaginal microbicide in a female population with genital HPV-infection: first experimental results. European Review for Medical and Pharmacological Sciences, 2019, 23, 6744-6752.	0.5	17
20	Correlation between the DNA fragmentation index (DFI) and sperm morphology of infertile patients. Journal of Assisted Reproduction and Genetics, 2021, 38, 979-986.	1.2	15
21	Socio-Demographic Characteristics and Sexual Behavioral Factors of Patients with Sexually Transmitted Infections Attending a Hospital in Southern Italy. International Journal of Environmental Research and Public Health, 2021, 18, 4722.	1.2	14
22	â€˜Secondary preventionâ€™ against female HPV infection: literature review of the role of carrageenan. Expert Review of Anti-Infective Therapy, 2020, 18, 865-874.	2.0	12
23	Use of fuzzy neural networks in modeling relationships of HPV infection with apoptotic and proliferation markers in potentially malignant oral lesions. Oral Oncology, 2005, 41, 994-1004.	0.8	11
24	Giant cell arteritis associated with chronic active Epstein-Barr virus infection. Reumatismo, 2013, 65, 36-9.	0.4	11
25	Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations. Scientific Reports, 2021, 11, 4096.	1.6	9
26	Atypical squamous cells of undetermined significance-favour reactive compared to atypical squamous cells of undetermined significance-favour dysplasia: association with cervical intraepithelial lesions and human papillomavirus infection. Journal of Clinical Virology, 2005, 33, 281-286.	1.6	8
27	The EBV-DNA Can be Used as a Diagnostic and Follow-up Parameter of the Rhinopharyngeal Tumors in the Non-Endemic Population of the Western Sicily. Indian Journal of Otolaryngology and Head and Neck Surgery, 2019, 71, 396-400.	0.3	7
28	Sexually Transmitted Diseases: Diagnosis and Control. International Journal of Environmental Research and Public Health, 2022, 19, 5293.	1.2	6
29	Cluster of Legionnairesâ€™ Disease in an Italian Prison. International Journal of Environmental Research and Public Health, 2019, 16, 2062.	1.2	5
30	Low Frequency of Human Papillomavirus in Strictly Site-Coded Oral Squamous Cell Carcinomas, Using the Latest NHI/SEER-ICD Systems: A Pilot Observational Study and Critical Review. Cancers, 2021, 13, 4595.	1.7	5
31	Genotyping and Antifungal Susceptibility of Dipodascus capitatus Isolated in a Neonatal Intensive Care Unit of a Sicilian Hospital. Advances in Experimental Medicine and Biology, 2017, 973, 81-88.	0.8	3
32	Predictive Role of the p16 Immunostaining Pattern in Atypical Cervical Biopsies with Less Common High Risk HPV Genotypes. Diagnostics, 2021, 11, 1947.	1.3	2
33	HPV-DNA Positive/p16 IHC Negative Oral Squamous Cell Carcinoma: A Case Report. Proceedings (mdpi), 2019, 35, .	0.2	0